Cytokinetics (NASDAQ:CYTK) Given New $96.00 Price Target at Citizens Jmp

Cytokinetics (NASDAQ:CYTK) had its price target lifted by equities research analysts at Citizens Jmp from $88.00 to $96.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s target price would indicate a potential upside of 36.95% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and issued a $90.00 price target on shares of Cytokinetics in a research report on Friday, January 9th. Leerink Partners set a $83.00 price objective on Cytokinetics in a research report on Monday, December 22nd. JPMorgan Chase & Co. boosted their price target on shares of Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, Royal Bank Of Canada boosted their target price on shares of Cytokinetics from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Sixteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.78.

Cytokinetics Stock Performance

Shares of CYTK opened at $70.10 on Wednesday. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98. The stock has a market capitalization of $8.57 billion, a price-to-earnings ratio of -11.14 and a beta of 0.54. The stock has a fifty day moving average of $64.14 and a 200-day moving average of $58.32.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the prior year, the business posted ($1.26) EPS. The company’s revenue was up 4.9% on a year-over-year basis. As a group, equities analysts forecast that Cytokinetics will post -5.24 EPS for the current year.

Insider Activity

In other Cytokinetics news, Director John T. Henderson sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $63.90, for a total transaction of $559,125.00. Following the completion of the sale, the director directly owned 74,578 shares of the company’s stock, valued at approximately $4,765,534.20. The trade was a 10.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 28,064 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $66.72, for a total value of $1,872,430.08. Following the completion of the transaction, the director owned 9,977 shares in the company, valued at $665,665.44. This represents a 73.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 151,385 shares of company stock valued at $9,817,158. 3.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its stake in Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Cytokinetics during the 4th quarter worth approximately $27,000. Kestra Advisory Services LLC purchased a new position in shares of Cytokinetics in the 4th quarter worth approximately $29,000. Quarry LP purchased a new position in shares of Cytokinetics in the 3rd quarter worth approximately $30,000. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Cytokinetics in the fourth quarter valued at approximately $32,000.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe; U.S. launch underway with first prescriptions dispensed within days — this turns near-term revenue into a tangible commercial story and is the biggest immediate catalyst. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue materially exceeded expectations: Q4 revenue ~$17.7M vs. consensus near $8M — suggests early commercial uptake or other revenue sources are ahead of models. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Strong balance sheet: company reported ~ $1.2 billion in cash, cash equivalents and investments as of 12/31/25 and provided 2026 financial guidance — gives runway to support commercialization and ongoing trials. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Near-term clinical catalyst: company expects to share ACACIA‑HCM topline results in Q2 2026 — a positive binary event that could drive further re-rating if favorable. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst views are mixed on CYTK’s near-term outlook — some focus on commercial upside while others remain cautious on uptake and margins. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
• Neutral Sentiment: Full earnings and call transcripts are available for details on commercialization plans and cost structure; useful for investors who want management tone and phasing. Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Small EPS miss and widening loss: GAAP EPS was -$1.50 vs. consensus -$1.48, and the loss increased versus prior year (-$1.26) — ongoing operating losses remain a drag until revenue scales. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.